Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity

Mikhail Binnewies, Adriana M. Mujal, Joshua L. Pollack, Alexis J. Combes, Emily A. Hardison, Kevin C. Barry, Jessica Tsui, Megan K. Ruhland, Kelly Kersten, Marwan A. Abushawish, Marko Spasic, Jonathan P. Giurintano, Vincent Chan, Adil I. Daud, Patrick Ha, Chun J. Ye, Edward W. Roberts, Matthew F. Krummel

Research output: Contribution to journalArticlepeer-review

149 Scopus citations


A subtype of conventional dendritic cells, cDC2, are able to prime CD4+ T cells for antitumor functions and the presence of cDC2 in human cancer samples may serve as a predictive biomarker for survival and response to immune checkpoint blockade.

Original languageEnglish (US)
Pages (from-to)556-571.e16
Issue number3
StatePublished - Apr 18 2019
Externally publishedYes


  • CD4 T cells
  • T cell priming
  • checkpoint blockade
  • dendritic cells
  • immunotherapy
  • regulatory T cells
  • tumor immunology
  • tumor microenvironment

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4<sup>+</sup> T Cell Immunity'. Together they form a unique fingerprint.

Cite this